Compare Icl Group Ltd (ICL) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Natera Inc. Common Stock — how do they compare? Icl Group Ltd trades at $4.99 (market cap $6.38B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 8.9× Icl Group Ltd's market cap, and Icl Group Ltd pays a 4.13% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Natera Inc. Common Stock for 0 Days on average.
| ICL | NTRA | |
|---|---|---|
Market Cap | $6.38B | $57.03B |
Volume | 1,104,238 | 1,131,157 |
Sector | Basic Materials | Health |
52-Week High | $6.80 | $425.64 |
52-Week Low | $4.80 | $179.42 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $9.02B | $56.18B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $4.99, up 1.01% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating expectations, and maintains a dividend of $0.06. Revenue for 2025 was $7.15B with a net income margin of 3.95%. Valuation metrics show a P/E of 20.75 and P/B of 1.05, while analyst consensus is a Hold with a $6.08 price target.
ICL faces headwinds from fertilizer industry challenges but shows earnings resilience. The stock offers a moderate upside to the consensus target, supported by cost-transformation plans. Risks include input cost pressures and competitive dynamics. Institutional interest is evident with Amundi increasing its stake by 49.7% in Q1 2026.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
